Chronic Lymphocytic Leukemia

Featured Article
First-Line Ibrutinib Treatment Shows Long-Term Efficacy, High PFS and OS Rates in CLL
Based on a median follow-up of four years, John Allen, MD, assistant professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine, New York-Presbyterian Hospital, explains how first-line ibrutinib-based treatment resulted in sustained efficacy with high…
Study Shows Treatment Combo Beneficial for Patients With CLL
William G. Wierda, MD, PhD, professor, Department of Leukemia, University of Texas MD Anderson Cancer Center, discusses the results of the Phase II CAPTIVATE study, and highlights how the use of…
Quality of Life Significantly Lower With Chronic Lymphocytic Leukemia
Whether on treatment regimens or watch-and-wait, researchers recently found that patients with chronic lymphocytic leukemia had significantly impaired quality of life compared with age-matched…

Newsfeed

First-Line Ibrutinib Treatment Shows Long-Term Efficacy, High PFS and OS Rates in CLL
Study Shows Treatment Combo Beneficial for Patients With CLL
Quality of Life Significantly Lower With Chronic Lymphocytic Leukemia
Adverse Events Affect Many Treated With Most Common CLL Regimens
Examining How Early Treatment Impacts CLL Outcomes
Measuring the Value of Prognostic Indexes for the Treatment of CLL
Improved Outcomes Associated With CD19-Specific CAR-T Therapy in CLL Patients
Exploring the Effectiveness of CAR T-Cell Injections for CLL Patients
View More

Insights

First-Line Ibrutinib Treatment Shows Long-Term Efficacy, High PFS and OS Rates in CLL
Based on a median follow-up of four years, John Allen, MD, assistant professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine, New York-Presbyterian Hospital, explains how first-line ibrutinib-based…
Study Shows Treatment Combo Beneficial for Patients With CLL
William G. Wierda, MD, PhD, professor, Department of Leukemia, University of Texas MD Anderson Cancer Center, discusses the results of the Phase II CAPTIVATE study, and highlights how the use of Ibrutinib plus Venetoclax confers high rates of…
Expert Perspective on the Latest Clinical Updates in CLL Treatment Options, Disease Burden
Lindsey Roeker, MD, physician, Memorial Sloan Kettering Cancer Center, breaks down the treatment landscape and disease burden commonly faced among patients with chronic lymphocytic lymphoma.
View More
Back to Top